Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 52

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 52
---
 | Doors open:   |     | 15:45 pm (CEST)                                   |
| − |     | Meeting time: |     | 16:00 pm (CEST)                                   |
| − |     | Place:        |     | At the premises of Baker McKenzie Switzerland AG, 
 Holbeinstrasse 30, 8034 Zurich, Switzerland.      |

Select one of the two options:

| ☐ |     | Yes, I will be personally present at the extraordinary shareholders’ meeting of NLS Pharmaceutics Ltd.; or                                                                                                                                                                |
| ☐ |     | No, I will be unable to attend the extraordinary shareholders’ meeting of NLS Pharmaceutics Ltd. personally and wish to give my power of attorney by completing the proxy form enclosed to and based on the instructions provided in the invitation dated         , 2025. |

| Date and place: |
| Name:           |
| Signature:      |

*****

Appendix 3 VOTE ON INTERNET Go to http://www.vstocktransfer.com/proxy Click on Proxy Voter Login and log-on using the below control number. Voting will be open until 11:59 p.m. (Eastern Time) September 25, 2025. CONTROL 

# VOTE BY EMAIL Mark, sign and date your proxy card and send it to vote@vstocktransfer.com. * SPECIMEN * 1 MAIN STREET ANYWHERE PA 99999-9999 * SPECIMEN * 1 MAIN STREET ANYWHERE PA 99999-9999 Please Vote, Sign, Date and Return Promptly in the Enclosed Envelope. Extraordinary Meeting of Shareholders Proxy Card - NLS Pharmaceutics Ltd. DETACH PROXY CARD HERE TO VOTE BY MAIL The Board of Directors recommends a vote “FOR” all listed Proposals. 1. Approval of the Merger Agreement on an advisory basis The board proposes to approve the Merger Agreement, that the Company has entered into on 4 November 2024 according to which it will merge with Kadimastem, in the sense of an advisory vote. 2. Par Value Reduction, Reverse split and Contribution in Kind The board proposes (i) to reduce the share capital and the participation capital by a reduction of the respective nominal values, (ii) to increase the share capital and the participation capital, (iii) to implement a reverse share split and (iv) to increase the share capital by way of a contribution in kind, in each case at the terms listed in